Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

General

General

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • General
  • Health Care
  • Hedge Funds
  • M&A
  • News
  • Rumors
  • Small Cap

Owl Creek Urges Cano Health Board To Consider Potential Sale

By Vandana Singh
August 23, 8:14 AM
Owl Creek Asset Management L.P. sent a letter to Cano Health Inc (NYSE: CANO) board 

AGL

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers & Shakers
  • Small Cap

KalVista Shares Climb As Late-Stage Label Extension Study On Skin Disorder Candidate Kicks-off

By Ragothaman Srinivasan
August 23, 8:10 AM
KalVista Pharmaceuticals (NASDAQ: KALV) has initiated the KONFIDENT-S open label extension (OLE) study for its ongoing Phase 3 study of sebetralstat for the on-demand treatment of hereditary angioedema (HAE) attacks.

KALV

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

Ensysce Biosciences Announces Completion Of Clinical Portion Of Human Abuse Potential Trial PF614-103

By Benzinga Newsdesk
August 23, 8:05 AM
Completion of Clinical Portion Represents Critical Milestone Towards Commercialization Nasal Opioid Abuse Being Explored for PF614 Data From Trial Expected in September 2022

ENSC

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

Inhibikase Therapeutics Announces Dosing Of First Patient In Its Phase 2a ‘201’ Clinical Trial Of IkT-148009 To Treat Parkinson’s Disease

By Benzinga Newsdesk
August 23, 8:04 AM
nhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced dosing of the

IKT

Read More
1 minute read
  • General
  • Media
  • News

Volkswagen Eyes Stake In Canadian Mining Business: Reuters

By Shivani Kumaresan
August 23, 7:38 AM
Volkswagen AG (OTC:VWAGY) is planning to enter the mining business in Canada, Reuters reported, citing Handelsblatt daily. The move will…

VWAGY

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News

Merck Gets FDA Fast Track Status For Chronic Kidney Disease Candidate

By Ragothaman Srinivasan
August 23, 7:29 AM
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE: MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD).

MRK

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

Synlogic Granted FDA Fast Track Designation For SYNB1353 For Treatment Of Homocystinuria (HCU)

By Bill Haddad
August 23, 7:05 AM
CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to

SYBX

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

Foghorn Therapeutics Announces FDA Has Placed A Clinical Hold On Phase I Dose Escalation Study Of FHD-286

By Bill Haddad
August 23, 7:04 AM
Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system,

FHTX

Read More
1 minute read
  • General

Tritium Highlights Opening Of First Global EV Fast Charger Manufacturing Facility In United States

By Bill Haddad
August 23, 6:34 AM
LEBANON, Tenn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Tritium DCFC Limited (NASDAQ:DCFC), a global leader in direct current (DC) fast chargers for electric vehicles (EVs), today celebrates the opening of its new EV fast

DCFC

Read More
1 minute read
  • General
  • Health Care
  • Large Cap
  • M&A
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

Alcon Buys Aerie Pharma For $770M To Enhance Its Ophthalmic Pharma Portfolio

By Vandana Singh
August 23, 6:16 AM
Alcon AG (NYSE:ALC) has agreed to acquire Aerie Pharmaceuticals Inc (NASDAQ:AERI) for $15.25 per share, valuing Aerie at about $770 million. The…

AERI

Posts pagination

Previous 1 … 2,206 2,207 2,208 … 2,367 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service